

REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH HYPERLIPIDEMIA

1. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE *et al*: **2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines** 2018;25709.
2. O'Malley PG, Arnold MJ, Kelley C, Spacek L, Buelt A, Natarajan S, Donahue MP, Vagichev E, Ballard-Hernandez J, Logan A *et al*: **Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline.** *Annals of internal medicine* 2020, **173**(10):822-829.
3. Tobe SW, Stone JA, Anderson T, Bacon S, Cheng AYY, Daskalopoulou SS, Ezekowitz JA, Gregoire JC, Gubitz G, Jain R *et al*: **Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update.** *Canadian Medical Association Journal* 2018, **190**(40):E1192.
4. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW *et al*: **2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.** *Circulation* 2019, **140**(11):e596-e646.
5. Anderson TJ, Gregoire J, Pearson GJ, Barry AR, Couture P, Dawes M, Francis GA, Genest J, Jr., Grover S, Gupta M *et al*: **2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult.** *The Canadian journal of cardiology* 2016, **32**(11):1263-1282.
6. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM *et al*: **2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.** *Circulation* 2014, **129**(25 Suppl 2):S1-45.
7. Rifkind BM: **Lipid Research Clinics Coronary Primary Prevention Trial: results and implications.** *Am J Cardiol* 1984, **54**(5):30c-34c.
8. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR *et al*: **2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.** *Eur Heart J* 2016, **37**(39):2999-3058.

9. Watts GF, Lewis B, Brunt JN, Lewis ES, Coltart DJ, Smith LD, Mann JI, Swan AV: **Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS).** *Lancet* 1992, **339**(8793):563-569.
10. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM *et al*: **Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.** *The New England journal of medicine* 2017, **376**(18):1713-1722.
11. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA *et al*: **Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.** 2018, **379**(22):2097-2107.
12. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM *et al*: **Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events.** 2015, **372**(16):1500-1509.
13. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M *et al*: **Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events.** 2015, **372**(16):1489-1499.
14. Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM: **Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.** *Eur Heart J* 2015, **36**(19):1186-1194.
15. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P *et al*: **Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.** *Lancet* 2005, **366**(9500):1849-1861.
16. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J *et al*: **Effects of combination lipid therapy in type 2 diabetes mellitus.** *The New England journal of medicine* 2010, **362**(17):1563-1574.
17. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V: **Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.** *Lancet* 2010, **375**(9729):1875-1884.
18. Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B: **Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis.** *Atherosclerosis* 2011, **217**(2):492-498.
19. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW *et al*: **Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.** *The New England journal of medicine* 2015, **372**(25):2387-2397.

20. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J *et al*: **The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.** *Lancet* 2011, **377**(9784):2181-2192.
21. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W: **Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.** *The New England journal of medicine* 2011, **365**(24):2255-2267.
22. Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R *et al*: **Effects of extended-release niacin with laropiprant in high-risk patients.** *The New England journal of medicine* 2014, **371**(3):203-212.
23. Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M *et al*: **The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.** *Clinical pharmacology and therapeutics* 2022, **111**(5):1007-1021.
24. Ivers NM, Jiang M, Alloo J, Singer A, Ngui D, Casey CG, Yu CH: **Diabetes Canada 2018 clinical practice guidelines: Key messages for family physicians caring for patients living with type 2 diabetes.** *Can Fam Physician* 2019, **65**(1):14-24.
25. Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini GB, McPherson R, Francis GA, Poirier P, Lau DC, Grover S *et al*: **2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult.** *The Canadian journal of cardiology* 2013, **29**(2):151-167.
26. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI *et al*: **AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.** *Endocr Pract* 2017, **23**(Suppl 2):1-87.
27. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM *et al*: **2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.** *Journal of the American College of Cardiology* 2014, **63**(25 Pt B):2889-2934.
28. NICE: **National Clinical Guideline CG181.** In: *Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease.* NICE; 2014.

29. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdtts E, Gohlke-Barwolf C, Holme I, Kesaniemi YA *et al*: **Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis**. *The New England journal of medicine* 2008, **359**(13):1343-1356.
30. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM *et al*: **Efficacy and safety of evolocumab in reducing lipids and cardiovascular events**. *The New England journal of medicine* 2015, **372**(16):1500-1509.
31. Keene D, Price C, Shun-Shin MJ, Francis DP: **Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients**. *Bmj* 2014, **349**:g4379.
32. Ip CK, Jin DM, Gao JJ, Meng Z, Meng J, Tan Z, Wang JF, Geng DF: **Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials**. *Int J Cardiol* 2015, **191**:138-148.
33. Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P: **Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis**. *J Cardiovasc Pharmacol* 2011, **57**(2):267-272.
34. Wilson PWF, Polonsky TS, Miedema MD, Khera A, Kosinski AS, Kuvin JT: **Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines**. *Journal of the American College of Cardiology* 2019, **73**(24):3210-3227.
35. Schmidt AF, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP: **PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease**. *The Cochrane database of systematic reviews* 2017, **4**:Cd011748.
36. Steffens D, Bramlage P, Scheeff C, Kasner M, Hassanein A, Friebe J, Rauch-Kröhnert U: **PCSK9 inhibitors and cardiovascular outcomes**. *Expert Opin Biol Ther* 2020, **20**(1):35-47.
37. Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, Maxwell WD, McLeod HL, Krauss RM, Roden DM *et al*: **The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update**. *Clin Pharmacol Ther* 2014, **96**(4):423-428.
38. **Dutch Guidelines**. [<https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf>]
39. **Dutch guidelines August 2020 update**
[https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf]

40. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhashi H, Urasaki Y *et al*: **Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics.** *Clin Pharmacol Ther* 2003, **73**(6):554-565.
41. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ *et al*: **High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1).** *Pharmacogenetics* 2004, **14**(7):429-440.
42. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T: **Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics.** *Clin Pharmacol Ther* 2004, **75**(5):415-421.
43. Niemi M, Neuvonen PJ, Hofmann U, Backman JT, Schwab M, Lutjohann D, von Bergmann K, Eichelbaum M, Kivisto KT: **Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17.** *Pharmacogenet Genomics* 2005, **15**(5):303-309.
44. Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB, Banerjee P, Milos PM, Myrand SP, Paulauskis J *et al*: **An association study of 43 SNPs in 16 candidate genes with atorvastatin response.** *Pharmacogenomics J* 2005, **5**(6):352-358.
45. Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lutjohann D, von Bergmann K, Eichelbaum M, Kivisto KT: **Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin.** *Clin Pharmacol Ther* 2006, **79**(5):419-426.
46. Hedman M, Antikainen M, Holmberg C, Neuvonen M, Eichelbaum M, Kivisto KT, Neuvonen PJ, Niemi M: **Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes.** *Br J Clin Pharmacol* 2006, **61**(6):706-715.
47. Zhang W, Chen BL, Ozdemir V, He YJ, Zhou G, Peng DD, Deng S, Xie QY, Xie W, Xu LY *et al*: **SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients.** *Br J Clin Pharmacol* 2007, **64**(3):346-352.
48. Ho RH, Choi L, Lee W, Mayo G, Schwarz UI, Tirona RG, Bailey DG, Stein CM, Kim RB: **Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants.** *Pharmacogenet Genomics* 2007, **17**(8):647-656.
49. Pasanen MK, Miettinen TA, Gylling H, Neuvonen PJ, Niemi M: **Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate.** *Pharmacogenet Genomics* 2008, **18**(10):921-926.

50. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS: **The SLCO1B1*5 genetic variant is associated with statin-induced side effects.** *J Am Coll Cardiol* 2009, **54**(17):1609-1616.
51. Ide T, Sasaki T, Maeda K, Higuchi S, Sugiyama Y, Ieiri I: **Quantitative population pharmacokinetic analysis of pravastatin using an enterohepatic circulation model combined with pharmacogenomic Information on SLCO1B1 and ABCC2 polymorphisms.** *J Clin Pharmacol* 2009, **49**(11):1309-1317.
52. Martin NG, Li KW, Murray H, Putt W, Packard CJ, Humphries SE: **The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin.** *Br J Clin Pharmacol* 2012, **73**(2):303-306.
53. Li Y, Sabatine MS, Tong CH, Ford I, Kirchgeßner TG, Packard CJ, Robertson M, Rowland CM, Bare LA, Shepherd J *et al*: **Genetic variants in the KIF6 region and coronary event reduction from statin therapy.** *Hum Genet* 2011, **129**(1):17-23.
54. Iakoubova OA, Robertson M, Tong CH, Rowland CM, Catanese JJ, Blauw GJ, Jukema JW, Murphy MB, Devlin JJ, Ford I *et al*: **KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study.** *Eur J Cardiovasc Prev Rehabil* 2010, **17**(4):455-461.
55. Shiffman D, Sabatine MS, Louie JZ, Kirchgeßner TG, Iakoubova OA, Campos H, Devlin JJ, Sacks FM: **Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial.** *Am J Cardiol* 2010, **105**(9):1300-1305.
56. Iakoubova OA, Tong CH, Rowland CM, Kirchgeßner TG, Young BA, Arellano AR, Shiffman D, Sabatine MS, Campos H, Packard CJ *et al*: **Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials.** *J Am Coll Cardiol* 2008, **51**(4):435-443.
57. Chasman DI, Posada D, Subrahmanyam L, Cook NR, Stanton VP, Jr., Ridker PM: **Pharmacogenetic study of statin therapy and cholesterol reduction.** *Jama* 2004, **291**(23):2821-2827.
58. Wan Z, Wang G, Li T, Xu B, Pei Q, Peng Y, Sun H, Cheng L, Zeng Y, Yang G *et al*: **Marked Alteration of Rosuvastatin Pharmacokinetics in Healthy Chinese with ABCG2 34G>A and 421C>A Homozygote or Compound Heterozygote.** *J Pharmacol Exp Ther* 2015, **354**(3):310-315.
59. Birmingham BK, Bujac SR, Elsby R, Azumaya CT, Wei C, Chen Y, Mosqueda-Garcia R, Ambrose HJ: **Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?** *Eur J Clin Pharmacol* 2015, **71**(3):341-355.

60. Birmingham BK, Bujac SR, Elsby R, Azumaya CT, Zalikowski J, Chen Y, Kim K, Ambrose HJ: **Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States.** *Eur J Clin Pharmacol* 2015, **71**(3):329-340.
61. Lee HK, Hu M, Lui S, Ho CS, Wong CK, Tomlinson B: **Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.** *Pharmacogenomics* 2013, **14**(11):1283-1294.
62. DeGorter MK, Tirona RG, Schwarz UI, Choi YH, Dresser GK, Suskin N, Myers K, Zou G, Iwuchukwu O, Wei WQ *et al*: **Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.** *Circ Cardiovasc Genet* 2013, **6**(4):400-408.
63. Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM: **Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.** *Circ Cardiovasc Genet* 2012, **5**(2):257-264.
64. Hu M, Lui SS, Mak VW, Chu TT, Lee VW, Poon EW, Tsui TK, Ko GT, Baum L, Tam LS *et al*: **Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients.** *Pharmacogenet Genomics* 2010, **20**(10):634-637.
65. Bailey KM, Romaine SP, Jackson BM, Farrin AJ, Efthymiou M, Barth JH, Copeland J, McCormack T, Whitehead A, Flather MD *et al*: **Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.** *Circ Cardiovasc Genet* 2010, **3**(3):276-285.
66. Tomlinson B, Hu M, Lee VW, Lui SS, Chu TT, Poon EW, Ko GT, Baum L, Tam LS, Li EK: **ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin.** *Clin Pharmacol Ther* 2010, **87**(5):558-562.
67. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M: **ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.** *Clin Pharmacol Ther* 2009, **86**(2):197-203.
68. Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, Fen J *et al*: **Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.** *Clin Chim Acta* 2006, **373**(1-2):99-103.
69. Danik JS, Chasman DI, MacFadyen JG, Nyberg F, Barratt BJ, Ridker PM: **Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy.** *Am Heart J* 2013, **165**(6):1008-1014.
70. Soko ND, Chimusa E, Masimirembwa C, Dandara C: **An African-specific profile of pharmacogene variants for rosuvastatin plasma variability: limited role for SLCO1B1 c.521T>C and ABCG2 c.421A>C.** *Pharmacogenomics J* 2019, **19**(3):240-248.

71. Kashihara Y, Ieiri I, Yoshikado T, Maeda K, Fukae M, Kimura M, Hirota T, Matsuki S, Irie S, Izumi N *et al*: **Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP**. *J Pharm Sci* 2017, **106**(9):2688-2694.
72. Puccetti L, Ciani F, Auteri A: **Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study**. *Atherosclerosis* 2010, **211**(1):28-29.
73. Ramakumari N, Indumathi B, Katkam SK, Kutala VK: **Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects**. *Indian Heart J* 2018, **70** Suppl 3:S120-S125.
74. Mega JL, Morrow DA, Brown A, Cannon CP, Sabatine MS: **Identification of genetic variants associated with response to statin therapy**. *Arterioscler Thromb Vasc Biol* 2009, **29**(9):1310-1315.
75. Thompson JF, Hyde CL, Wood LS, Paciga SA, Hinds DA, Cox DR, Hovingh GK, Kastelein JJ: **Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort**. *Circ Cardiovasc Genet* 2009, **2**(2):173-181.
76. Voora D, Shah SH, Reed CR, Zhai J, Crosslin DR, Messer C, Salisbury BA, Ginsburg GS: **Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response**. *Circ Cardiovasc Genet* 2008, **1**(2):100-106.
77. Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, Visscher H, Jukema JW, Stalenhoef AF, Ross CJ *et al*: **Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin**. *Pharmacogenomics J* 2012, **12**(3):233-237.
78. Santos PC, Gagliardi AC, Miname MH, Chacra AP, Santos RD, Krieger JE, Pereira AC: **SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia**. *Eur J Clin Pharmacol* 2012, **68**(3):273-279.
79. Rodrigues AC, Perin PM, Purim SG, Silbiger VN, Genvigir FD, Willrich MA, Arazi SS, Luchessi AD, Hirata MH, Bernik MM *et al*: **Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response**. *Int J Mol Sci* 2011, **12**(9):5815-5827.
80. Lee YJ, Lee MG, Lim LA, Jang SB, Chung JY: **Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects**. *Int J Clin Pharmacol Ther* 2010, **48**(1):36-45.
81. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M: **Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin**. *Clin Pharmacol Ther* 2007, **82**(6):726-733.

82. Marciante KD, Durda JP, Heckbert SR, Lumley T, Rice K, McKnight B, Totah RA, Tamraz B, Kroetz DL, Fukushima H *et al*: **Cerivastatin, genetic variants, and the risk of rhabdomyolysis.** *Pharmacogenet Genomics* 2011, **21**(5):280-288.
83. Krauss RM, Mangravite LM, Smith JD, Medina MW, Wang D, Guo X, Rieder MJ, Simon JA, Hulley SB, Waters D *et al*: **Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment.** *Circulation* 2008, **117**(12):1537-1544.
84. Mangravite LM, Engelhardt BE, Medina MW, Smith JD, Brown CD, Chasman DI, Mecham BH, Howie B, Shim H, Naidoo D *et al*: **A statin-dependent QTL for GATM expression is associated with statin-induced myopathy.** *Nature* 2013, **502**(7471):377-380.
85. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH: **Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males.** *Pharmacogenomics* 2009, **10**(11):1743-1751.
86. Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Hutz MH: **The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment.** *Clin Pharmacol Ther* 2005, **78**(5):551-558.
87. Lipworth BJ, Basu K, Donald HP, Tavendale R, Macgregor DF, Ogston SA, Palmer CN, Mukhopadhyay S: **Tailored second-line therapy in asthmatic children with the Arg(16) genotype.** *Clin Sci (Lond)* 2013, **124**(8):521-528.
88. Luzum JA, Theusch E, Taylor KD, Wang A, Sadee W, Binkley PF, Krauss RM, Medina MW, Kitzmiller JP: **Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations.** *J Cardiovasc Pharmacol* 2015, **66**(1):80-85.
89. Oh J, Ban MR, Miskie BA, Pollex RL, Hegele RA: **Genetic determinants of statin intolerance.** *Lipids Health Dis* 2007, **6**:7.
90. de Keyser CE, Eijgelsheim M, Hofman A, Sijbrands EJ, Maitland-van der Zee AH, van Duijn CM, Uitterlinden AG, Witteman JC, Ch Stricker BH: **Single nucleotide polymorphisms in genes that are associated with a modified response to statin therapy: the Rotterdam Study.** *Pharmacogenomics J* 2011, **11**(1):72-80.
91. Donnelly LA, Doney AS, Tavendale R, Lang CC, Pearson ER, Colhoun HM, McCarthy MI, Hattersley AT, Morris AD, Palmer CN: **Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study.** *Clin Pharmacol Ther* 2011, **89**(2):210-216.
92. Donnelly LA, van Zuydam NR, Zhou K, Tavendale R, Carr F, Maitland-van der Zee AH, Leusink M, de Boer A, Doevendans PA, Asselbergs FW *et al*: **Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-**

analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment.
Pharmacogenet Genomics 2013, **23**(10):518-525.

93. de Keyser CE, Peters BJ, Becker ML, Visser LE, Uitterlinden AG, Klungel OH, Verstuyft C, Hofman A, Maitland-van der Zee AH, Stricker BH: **The SLC01B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.** *Pharmacogenet Genomics* 2014, **24**(1):43-51.
94. Postmus I, Trompet S, Deshmukh HA, Barnes MR, Li X, Warren HR, Chasman DI, Zhou K, Arsenault BJ, Donnelly LA *et al*: **Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins.** *Nat Commun* 2014, **5**:5068.
95. Leusink M, Maitland-van der Zee AH, Ding B, Drenos F, van Iperen EP, Warren HR, Caulfield MJ, Cupples LA, Cushman M, Hingorani AD *et al*: **A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering.** *Pharmacogenomics* 2016, **17**(6):583-591.
96. Wei WQ, Li X, Feng Q, Kubo M, Kullo IJ, Peissig PL, Karlson EW, Jarvik GP, Lee MTM, Shang N *et al*: **LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins.** *Circulation* 2018, **138**(17):1839-1849.
97. Upjohn Canada ULC: **Lipitor (atorvastatin).** In: *CA Product Monograph*. Kirkland, QC; 2020.
98. Parke-Davis Div of Pfizer Inc: **Lipitor (atorvastatin).** In: *US Product Monograph*. New York, NY; 2020.
99. Canadian_Pharmacists_Association: **HMG-CoA Reductase Inhibitors (Statins).** In: *CPhA Monograph*. 2015.
100. Roederer GO: **Dyslipidemias.** In: *Compendium of Therapeutic Choices*. Apr 2018 edn. Ottawa, Ontario: Canadian Pharmacists Association 2018.
101. Regier L, Jensen B: **LIPID LOWERING THERAPY: Drug Comparison Chart** In: *RxFiles*. vol. 11th ed. Saskatoon, SK: Saskatoon Health Region; 2018.
102. Novartis Pharmaceuticals Canada Inc: **Lescol XL (fluvastatin).** In: *CA Product Monograph*. Dorval, QC; 2019.
103. Novartis Pharmaceuticals Corporation: **Lescol XL (fluvastatin).** In: *US Product Monograph*. East Hanover, NJ; 2020.
104. Sanis Health Inc: **Lovastatin.** In: *CA Product Monograph*. Brampton, ON; 2017.
105. Covis Pharma: **Altoprev (lovastatin).** In: *US Product Monograph*. Zug, Switzerland; 2020.

106. Actavis Pharma Inc: **Lovastatin**. In: *US product Monograph*. Parsippany, NJ; 2020.
107. Kowa Pharmaceuticals America Inc: **Livalo (pitavastatin calcium)**. In: *US Product Monograph*. Montgomery, AL; 2019.
108. Medicure International Inc: **Zypitamag (pitavastatin magnesium)**. In: *US Product Monograph*. Princeton, NJ; 2020.
109. Apotex Inc: **Apo-pravastatin**. In: *CA Prodcut Monograph*. Toronto, ON; 2020.
110. E.R. Squibb & Sons: **Pravachol (pravastatin)**. In: *US Product Monograph*. Princeton, NJ; 2020.
111. AstraZeneca Canada Inc: **Crestor (rosuvastatin)**. In: *CA Product Monograph*. Mississauga, ON; 2020.
112. AstraZeneca Pharmaceuticals LP: **Crestor (rosuvastatin)**. In: *US Product Monograph*. Wilmington, DE; 2020.
113. Merck Canada Inc: **Zocor (simvastatin)**. In: *CA Product Monograph*. Kirkland, QC; 2019.
114. Merck Sharp & Dohme Corp: **Zocor (simvastatin)**. In: *US Product Monograph*. Whitehouse Station, NJ; 2020.
115. Pharmascience: **Cholestyramine_Olestyr**. In: *Product Monograph*. Montreal, Quebec: Pharmascience Inc.; 2017.
116. Upsher-Smith Laboratories LLC: **Prevalite (cholestyramine)**. In: *US Product Monograph*. Maple Grove, MN; 2020.
117. CPhA: **Cholestyramine**. In: *CPhA Monograph*. Ottawa, ON: Canadian Pharmacists Association; 2017.
118. Lee M JB, Regier L: **Lipid lowering therapy: Drug comparison chart**. In: *RxFiles*. Saskatoon, SK: Saskatoon Health Region; 2019.
119. Bausch Health Canada Inc: **Lodalis (colesevelam)**. In: *CA Product Monograph*. Laval, QC; 2020.
120. Glenmark: **Colesevelam**. In: *Product Monograph*. Mahwah, NJ: Glenmark Pharmaceuticals Inc; 2019.
121. DaiichiSankyo: **Colesevelam_Welchol**. In: *FDA Product Monograph*. Basking Ridge, NJ: Daiichi Sankyo, Inc; 2019.
122. Pfizer Canada ULC: **Colestid (colestipol)**. In: *CA Product Monograph*. Kirkland, QC; 2020.

123. Amneal: **Colestipol**. In: *Product Monograph*. Bridgewater, NJ: Amneal Pharmaceuticals LLC; 2019.
124. PharmaciaandUpjohn: **Colestipol_Colestid**. In: *FDA Product Monograph*. NY, NY: Pharmacia and Upjohn Company LLC; 2019.
125. SanofiAventis: **Alirocumab_Praluent**. In: *Product Monograph*. Laval, Quebec: Sanofi-aventis Canada Inc.; 2019.
126. Sanofi-Aventis US LLC: **Praluent (alirocumab)**. In: *US Product Monograph*. Bridgewater, NJ; 2020.
127. Amgen: **Evolocumab_Repatha**. In: *Product Monograph*. Mississauga, ON: Amgen Canada Inc.; 2019.
128. Amgen Inc: **Repatha (evolocumab)**. In: *US Product Monograph*. Thousand Oaks, CA; 2021.
129. AA PHARMA INC: **Fenofibrate**. In: *CA Product Monograph*. 2019.
130. ANI_Pharmaceuticals: **Fenofibrate_Capsule**. In: *FDA Product Monograph*. Baudette, MN: ANI Pharmaceuticals, Inc; 2019.
131. Apotex: **Fenofibrate**. In: *FDA Product Monograph*. Weston, Florida: Apotex Corp.; 2018.
132. Mylan: **Fenofibrate**. In: *FDA Product Monograph*. Morgantown, WV: Mylan Pharmaceuticals Inc.; 2019.
133. CPhA: **Fibric Acid Derivatives (Fibrates)**. In: *CPhA Monograph*. Ottawa, ON: Canadian Pharmacists Association; 2015.
134. Teva: **Gemfibrozil**. In: *Product Monograph*. Toronto, Canada: Teva Canada Limited; 2015.
135. Parke-Davis Div of Pfizer Inc: **Lopid (Gemfibrozil)**. In: *US Product Monograph*. New York, NY; 2020.